CSL has been granted a patent for a method using alpha-1 antitrypsin (A1AT) to prevent graft versus host disease (GVHD) in patients undergoing hematopoietic cell transplantation (HCT). The method involves specific dosages of A1AT before and after the procedure, potentially reducing the risk of acute GVHD. GlobalData’s report on CSL gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights CSL Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on CSL, Personalized cancer vaccines was a key innovation area identified from patents. CSL's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11857610B2) discloses a method aimed at reducing the risk of acute graft versus host disease (aGVHD) in individuals undergoing hematopoietic cell transplantation (HCT). The method involves administering alpha-1 antitrypsin (A1AT) in specific doses and schedules before and after the HCT procedure. By following the outlined regimen, the treatment not only reduces the risk of aGVHD but also potentially lowers the chances of chronic graft versus host disease (cGvHD) in the recipient.

The patent details various aspects of the method, including the dosage and frequency of A1AT administration post-HCT, the potential combination with immunosuppressive agents, and the continuation of A1AT treatment for a specified duration after the procedure. Additionally, the method is applicable to individuals with a range of hematologic disorders such as leukemia, lymphoma, myeloma, and genetic hematopoietic disorders. The patent also covers scenarios where the HCT procedure involves cells from related or unrelated donors, further expanding the scope of its application. Overall, the method outlined in the patent offers a promising approach to mitigating the risks associated with aGVHD and cGvHD in HCT recipients, potentially improving outcomes for individuals undergoing these procedures.

To know more about GlobalData’s detailed insights on CSL, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies